The US Food and Drug Administration (FDA) has granted approval to medical device firm Nevro‘s surgical leads, designed to be used with the Senza Spinal Cord Stimulation (SCS) System delivering HF10 Therapy.

The Senza system is claimed being the only SCS system, an evidence-based neuromodulation platform that delivers Nevro’s patented HF10 therapy, which is an SCS therapy issuing electrical pulses to the spinal cord to decrease pain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The electrical pulses are delivered by small electrodes on leads, which are placed at the vicinity of the spinal cord and connected to a compact, battery-powered generator implanted under the skin.

HF10 therapy is the only SCS therapy indicated to provide pain relief without paresthesia, and comparative pivotal study has proved that HF10 is the first such SCS therapy to exhibit better results when compared to the existing SCS for back and leg pain.

" … With the ability to use surgical leads with the Senza SCS system, I look forward to providing Nevro’s therapy to a broader set of patients."

Paresthesia is a stimulation-induced sensation, such as tingling or buzzing, which is the basis of traditional SCS.

Thomas Jefferson University Neurosurgery professor and programme director Dr Ashwini Sharan said: "In my practice, I have already witnessed the significant advantages of HF10 therapy, which provides superior pain relief for chronic back and leg pain patients.

"Now, with the ability to use surgical leads with the Senza SCS system, I look forward to providing Nevro’s therapy to a broader set of patients."

Nevro’s innovations in SCS, including the Senza system and HF10 therapy, are utilised by more than 85 issued US and international patents.